Street Calls of the Week
MoonLake Immunotherapeutics stock reached a new 52-week high, hitting 58.3 USD, with the company now commanding a market capitalization of $3.7 billion. According to InvestingPro analysis, the stock appears overvalued at current levels. This milestone comes as the company experiences a notable 1-year change, with its stock price increasing by 25.29%. The surge reflects positive investor sentiment, with analysts setting price targets ranging from $64 to $104. InvestingPro data reveals several more key insights about MLTX’s momentum and financial health, available in the comprehensive Pro Research Report. The 52-week high marks a significant point for MoonLake Immunotherapeutics, as it continues to build momentum in the market. The company has shown particularly strong performance over the past six months, posting a 33.5% return. Investors are closely watching the company’s developments and market performance, contributing to the stock’s upward trajectory. For deeper insights into MLTX’s valuation and growth prospects, visit InvestingPro, where you’ll find exclusive analysis and 13 additional ProTips.
In other recent news, Moonlake Immunotherapeutics has been the focus of multiple analyst ratings and acquisition rumors. Guggenheim reiterated its Buy rating with an $80.00 price target, following Moonlake’s second-quarter 2025 financial results. The firm noted that the company’s Phase III VELA clinical trial results for sonelokimab in hidradenitis suppurativa are on track for release around September 2025. Clear Street also reiterated its Buy rating, setting a $108.00 price target, showing confidence in Moonlake’s SLK therapy as a potential blockbuster treatment. RBC Capital maintained its Outperform rating with a $67 price target, highlighting the strong catalyst-driven potential of the company amid speculation about a potential acquisition by Merck. Reports suggest that Merck proposed a bid exceeding $3 billion earlier this year, although the initial offer was declined. The Financial Times reported that Merck is still interested in acquiring Moonlake to strengthen its drug pipeline, with insiders suggesting negotiations may resume. Guggenheim analysts also reaffirmed their Buy rating amid these merger and acquisition discussions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.